{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:12:48Z","timestamp":1788901968771,"version":"build-2803163510"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:p>\n                    A 55-year-old man with multiple myeloma (MM) underwent\n                    <jats:sup>68<\/jats:sup>\n                    Ga-pentixafor PET\/CT. An extramedullary soft-tissue lesion was initially misdiagnosed as a mesenchymal tumor due to low tracer avidity and marked uptake heterogeneity (bone marrow SUVmax 21.8 vs. extramedullary lesion SUVmax 4.1). The patient received standard anti-myeloma therapy for presumed medullary-limited MM. After 4 months, bone marrow disease was controlled, but the isolated extramedullary soft-tissue lesion showed increased\n                    <jats:sup>68<\/jats:sup>\n                    Ga-pentixafor uptake and enlarged size. Immunohistochemistry confirmed the extramedullary lesion to be an extramedullary disease (EMD) originating from MM. This case highlights the diagnostic challenges of low-CXCR4-avid extramedullary lesions.\n                  <\/jats:p>","DOI":"10.1097\/rlu.0000000000006612","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T13:05:32Z","timestamp":1785762332000},"page":"911-913","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Heterogeneity and Evolution of 68Ga-Pentixafor PET\/CT Signals in Extramedullary Multiple Myeloma"],"prefix":"10.1097","volume":"51","author":[{"given":"Mengjing","family":"Ji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutong","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0267-7819","authenticated-orcid":false,"given":"Fei","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"key":"R1-20260908","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1182\/blood-2006-07-035857","article-title":"Mechanisms of regulation of CXCR4\/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma","volume":"109","author":"Alsayed","year":"2007","journal-title":"Blood"},{"key":"R2-20260908","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13550-025-01368-7","article-title":"Establishment and validation of a clinical threshold criteria for choosing PET imaging tracers for indolent non-Hodgkin\u2019s lymphoma","volume":"16","author":"Yu","year":"2025","journal-title":"EJNMMI Res"},{"key":"R3-20260908","doi-asserted-by":"crossref","first-page":"5189","DOI":"10.1007\/s00259-025-07415-8","article-title":"Added value of multiparametric MRI for diagnosing subcentimeter functional adrenal nodules in primary aldosteronism using CXCR4-targeted PET\/MRI","volume":"52","author":"Meng","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R4-20260908","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1007\/s00259-024-06621-0","article-title":"[(68)Ga]Pentixafor PET\/CT for staging and prognostic assessment of newly diagnosed multiple myeloma: comparison to [(18)F]FDG PET\/CT","volume":"51","author":"Chen","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R5-20260908","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00259-019-04605-z","article-title":"Chemokine receptor-4 targeted PET\/CT with (68)Ga-Pentixafor in assessment of newly diagnosed multiple myeloma: comparison to (18)F-FDG PET\/CT","volume":"47","author":"Pan","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R6-20260908","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3324\/haematol.2012.065698","article-title":"Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents","volume":"97","author":"Usmani","year":"2012","journal-title":"Haematologica"},{"key":"R7-20260908","doi-asserted-by":"crossref","first-page":"132","DOI":"10.6004\/jnccn.2025.0023","article-title":"NCCN Guidelines\u00ae insights: Multiple Myeloma, Version 1.2025","volume":"23","author":"Kumar","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"R8-20260908","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/s41571-025-01041-x","article-title":"EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma","volume":"22","author":"Dimopoulos","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"R9-20260908","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s00277-013-1722-4","article-title":"Disseminated plasmacytomas in multiple myeloma: atypical presentations on multimodality images, emphasized on PET\/CT","volume":"92","author":"Yi","year":"2013","journal-title":"Ann Hematol"},{"key":"R10-20260908","doi-asserted-by":"crossref","first-page":"226","DOI":"10.2967\/jnumed.121.261906","article-title":"Tumor sink effect in (68)Ga-PSMA-11 PET: myth or reality?","volume":"63","author":"Gafita","year":"2022","journal-title":"J Nucl Med"},{"key":"R11-20260908","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s40644-025-00910-z","article-title":"The tumour sink effect on (68)Ga-PSMA-PET\/CT in metastatic castration-resistant prostate cancer and its implications for PSMA-RPT: a sub-analysis of the 3TMPO study","volume":"25","author":"Zamanian","year":"2025","journal-title":"Cancer Imaging"},{"key":"R12-20260908","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s00259-011-1937-3","article-title":"The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy","volume":"39","author":"Beauregard","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006612","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:01:01Z","timestamp":1788901261000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":12,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006612","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"assertion":[{"value":"2026-04-20","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}